Available Technologies

Browse Penn-owned technologies available for licensing.

Search Results - immunoncology

9 Results Sort By:

Neuroprotection in TBI/Concussion via Dietary Supplement

A dietary supplement that protects brain cells from the effects of TBI and concussion Problem: Traumatic brain injury (TBI) is a major cause of death and disability. Mild TBIs (such as concussion) are particularly common for athletes and warfighters and can produce disabilities without immediate brain cell death. This may be due to damage to...

Published: 11/15/2021

Inventor(s):

Keywords(s):

Category(s):

Tumor suppression by retinoic acid pathway inhibition

­ Targeting retinoic acid (RA) synthesizing enzymes or RA receptors with small molecules boosts the immune system towards a tumor rejection response Problem: Hepatocellular carcinoma (HCC) is the most common liver cancer globally. In the US alone, 33 000 patients are diagnosed yearly, 27 000 of which will die. Once metastasized, HCC shows...

Published: 11/11/2021

Inventor(s):

Keywords(s):

Category(s):

Gum-health promoting smart dental implant system

Dental implant that inhibits plaque accumulation and gingival tissue inflammation by photobiomodulation therapy delivered by embedded light-emitting diodes (LEDs) powered by electricity generated from the patient’s own oral motion. Problem: More than half of adults will lose one or more teeth in their lifetime. When a patient loses a tooth the...

Published: 2/9/2021

Inventor(s):

Keywords(s):

Category(s):

High performance CRISPR-Cas12a system for combinatorial genetic manipulation

CRISPR-Cas12a allowing for simultaneous editing of multiple genes in mammalian cells Problem: CRISPR-based gene editing technique has revolutionized the field of molecular biology. While CRISPR-Cas9-based methods are effectively used for single-gene knockout, multiplex gene editing remains a major challenge. Unlike Cas9, Cas12a can be used for multigene...

Published: 11/5/2020

Inventor(s):

Keywords(s):

Category(s):

Antibodies for targeting CAR-T cells to acute Myeloid Leukemia cells

Technology Overview: Acute myeloid leukemia (AML) is a major form of acute leukemia in elder adults. The treatment of AML has changed little in the past decades and the overall 5-year survival rate remains very poor in the AML patients. AML relapsed from chemotherapy is highly aggressive with poor prognosis. While adaptive cell therapy via chimeric...

Published: 11/5/2020

Inventor(s):

Keywords(s):

Category(s):

Antibody discovery platform for CAR-T cell targeting and drug conjugation

Technology Overview: Screening platform for identification of potent and specific nanobodies for (i) directing CAR-T cells to cancer cells, (ii) drug conjugation, or (iii) tumor imaging or diagnosis. Identification of antibodies capable of mediating CAR-T killing is challenging due to several reasons. First, the antibody has to have certain affinity...

Published: 11/2/2020

Inventor(s):

Keywords(s):

Category(s):

Rapid and ultrasensitive profiling of EGFRvIII mutations in cancer and normal tissue

A method to rapidly detect the presence of EGFRvIII mutations in cancers and normal tissue using digital PCR. Problem: Glioblastoma multiforme (GBM) is a devastating brain cancer with poor prognosis. EGFRvIII is a mutation in the Extracellular Growth Factor Receptor that frequently occurs in GBM tumors. Targeting EGFRvIII mutations is an emerging...

Published: 10/5/2020

Inventor(s):

Keywords(s):

Category(s):

Antibodies for targeting CAR-T cells to neuroendocrine tumors

Technology Overview: Neuroendocrine tumors (NETs) pose serious threats to patients’ well-being as malignant diseases, and most patients with metastatic NETs succumb to the disease. Using Sequential Tumor-related Antibody and antigen Retrieving (STAR) technology Dr. Xianxin Hua, MD, PhD at the University of Pennsylvania Medical School and his...

Published: 3/20/2020

Inventor(s):

Keywords(s):

Category(s):

Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells

The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...

Published: 1/29/2020

Inventor(s):

Keywords(s):

Category(s):